Study: MRS detects chemotherapy response earlier than CT, MRI

09/2/2008 | HealthImaging.com

Researchers were able to determine more quickly whether patients with recurring malignant brain tumors were responding to chemotherapy with the aid of metabolic imaging using magnetic resonance spectroscopy or with anatomic imaging using conventional MRI and CT scans. An added benefit of MRS imaging is that it does not expose patients to radiation, the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA